We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Core Laboratories (CLB) Q1 Earnings Meet Estimates, Up Y/Y
Read MoreHide Full Article
Core Laboratories N.V. (CLB - Free Report) reported first-quarter 2018 adjusted earnings of 57 cents per share, in line with the Zacks Consensus Estimate. This compares favorably with the prior-year quarter figure of 41 cents. The results were driven by improved performance of the Product Enhancement segment.
Total revenues of $170 million were marginally below the Zacks Consensus Estimate of $171 million. Revenues were up more than 8.5% from the prior-year quarter level of $156.6 million.
Core Laboratories N.V. Price, Consensus and EPS Surprise
Reservoir Description: This segment’s revenues were $100.8 million compared with $104.9 million in first-quarter 2017.
Operating income for the segment was about $14.8 million in the quarter compared with $15.9 million in the prior-year quarter. Operating margin of the segment was 15%.
Production Enhancement: Segment revenues were approximately $69.2 million in the quarter compared with $51.7 million in first-quarter 2017. Increased demand for the company’s advanced technology solutions helped in generating higher revenues.
Operating income for the segment was about $17.7 million in the quarter compared with $7.7 million in the prior-year quarter, reflecting a surge of 128.1%. Operating margin of the segment was 26%. Improved utilization, and higher-technology services and products drove margins.
Balance Sheet & Free Cash Flow
As of Mar 31, 2018, Core Laboratories had cash and cash equivalents of $13.2 million and long-term debt (including lease obligations) of around $235.1 million. The debt-to-capitalization ratio of the company was 60.8%.
Capital expenditures in the first quarter were $4.4 million, reflecting a year-over-year decline of 31%.
The company generated free cash flow of approximately $18.6 million in the quarter under review.
Quarterly Dividend
On Apr 17, the board of directors announced a cash dividend of 55 cents per share. Notably, this is same as the previous payout. The dividend will be paid on May 22 to shareholders of record on Apr 27.
Guidance
For second-quarter 2018, Core Laboratories expects earnings to be around 64-68 cents per share. The company expects second-quarter revenues in the range of $177-179 million while operating income is expected to lie between $36.2 million and 37.2 million. The company expects operating margin to be more than 20% in second-quarter 2018.
Zacks Rank & Key Picks
Core Laboratories currently has a Zacks Rank #3 (Hold).
Some better-ranked players in the same industry are C&J Energy Services , Solaris Oilfield Infrastructure (SOI - Free Report) and Archrock, Inc. (AROC - Free Report) . While C&J Energy and Solaris Oilfield sport a Zacks Rank #1 (Strong Buy), Archrock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
C&J Energy is expected to witness a year-over-year increase of 2,278.6% in 2018 earnings.
Solaris Oilfield is expected to witness a year-over-year increase of 262.5% in 2018 earnings.
Archrock is expected to witness a year-over-year increase of 195% in 2018 earnings.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Core Laboratories (CLB) Q1 Earnings Meet Estimates, Up Y/Y
Core Laboratories N.V. (CLB - Free Report) reported first-quarter 2018 adjusted earnings of 57 cents per share, in line with the Zacks Consensus Estimate. This compares favorably with the prior-year quarter figure of 41 cents. The results were driven by improved performance of the Product Enhancement segment.
Total revenues of $170 million were marginally below the Zacks Consensus Estimate of $171 million. Revenues were up more than 8.5% from the prior-year quarter level of $156.6 million.
Core Laboratories N.V. Price, Consensus and EPS Surprise
Core Laboratories N.V. Price, Consensus and EPS Surprise | Core Laboratories N.V. Quote
Segment Performance
Reservoir Description: This segment’s revenues were $100.8 million compared with $104.9 million in first-quarter 2017.
Operating income for the segment was about $14.8 million in the quarter compared with $15.9 million in the prior-year quarter. Operating margin of the segment was 15%.
Production Enhancement: Segment revenues were approximately $69.2 million in the quarter compared with $51.7 million in first-quarter 2017. Increased demand for the company’s advanced technology solutions helped in generating higher revenues.
Operating income for the segment was about $17.7 million in the quarter compared with $7.7 million in the prior-year quarter, reflecting a surge of 128.1%. Operating margin of the segment was 26%. Improved utilization, and higher-technology services and products drove margins.
Balance Sheet & Free Cash Flow
As of Mar 31, 2018, Core Laboratories had cash and cash equivalents of $13.2 million and long-term debt (including lease obligations) of around $235.1 million. The debt-to-capitalization ratio of the company was 60.8%.
Capital expenditures in the first quarter were $4.4 million, reflecting a year-over-year decline of 31%.
The company generated free cash flow of approximately $18.6 million in the quarter under review.
Quarterly Dividend
On Apr 17, the board of directors announced a cash dividend of 55 cents per share. Notably, this is same as the previous payout. The dividend will be paid on May 22 to shareholders of record on Apr 27.
Guidance
For second-quarter 2018, Core Laboratories expects earnings to be around 64-68 cents per share. The company expects second-quarter revenues in the range of $177-179 million while operating income is expected to lie between $36.2 million and 37.2 million. The company expects operating margin to be more than 20% in second-quarter 2018.
Zacks Rank & Key Picks
Core Laboratories currently has a Zacks Rank #3 (Hold).
Some better-ranked players in the same industry are C&J Energy Services , Solaris Oilfield Infrastructure (SOI - Free Report) and Archrock, Inc. (AROC - Free Report) . While C&J Energy and Solaris Oilfield sport a Zacks Rank #1 (Strong Buy), Archrock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
C&J Energy is expected to witness a year-over-year increase of 2,278.6% in 2018 earnings.
Solaris Oilfield is expected to witness a year-over-year increase of 262.5% in 2018 earnings.
Archrock is expected to witness a year-over-year increase of 195% in 2018 earnings.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>